ALK and non-small cell lung carcinoma: Here, we report a previously unidentified YAP‐mediated mechanism of acquired resistance to crizotinib in ALK‐positive NSCLC using in vitro and in vivo models with subsequent validation in patient samples before and/or after ALK inhibitor therapy.